These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 1279335)

  • 1. Heparin resistance after aprotinin.
    Fisher AR; Bailey CR; Shannon CN; Wielogorski AK
    Lancet; 1992 Nov; 340(8829):1230-1. PubMed ID: 1279335
    [No Abstract]   [Full Text] [Related]  

  • 2. Aprotinin and heparin monitoring during cardiopulmonary bypass.
    Hunt BJ; Segal H; Yacoub M
    Circulation; 1992 Nov; 86(5 Suppl):II410-2. PubMed ID: 1385011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass.
    Terrell MR; Walenga JM; Koza MJ; Pifarré R
    Ann Thorac Surg; 1996 Aug; 62(2):506-11. PubMed ID: 8694614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
    Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
    Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
    de Smet AA; Joen MC; van Oeveren W; Roozendaal KJ; Harder MP; Eijsman L; Wildevuur CR
    J Thorac Cardiovasc Surg; 1990 Oct; 100(4):520-7. PubMed ID: 1699088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety issues in heparin and protamine administration for extracorporeal circulation.
    Jobes DR
    J Cardiothorac Vasc Anesth; 1998 Apr; 12(2 Suppl 1):17-20. PubMed ID: 9583571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass.
    Hunt BJ; Segal HC; Yacoub M
    J Thorac Cardiovasc Surg; 1992 Jul; 104(1):211-2. PubMed ID: 1377315
    [No Abstract]   [Full Text] [Related]  

  • 9. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
    Levy JH; Salmenpera MT
    J Thorac Cardiovasc Surg; 1991 Nov; 102(5):802. PubMed ID: 1719304
    [No Abstract]   [Full Text] [Related]  

  • 10. Systemic thromboses after cardiopulmonary bypass: is it thrombin or antithrombin?
    Tanaka KA; Sniecinski R
    Anesthesiology; 2006 Aug; 105(2):428; author reply 428-9. PubMed ID: 16871082
    [No Abstract]   [Full Text] [Related]  

  • 11. Anticoagulation policy during use of aprotinin in cardiopulmonary bypass.
    van Oeveren W; van Oeveren B; Wildevuur CR
    J Thorac Cardiovasc Surg; 1992 Jul; 104(1):210-1. PubMed ID: 1377314
    [No Abstract]   [Full Text] [Related]  

  • 12. [Aprotinin and monitoring of heparin level during cardiopulmonary bypass: preliminary report].
    Tabuchi N; van Oeveren W
    Nihon Geka Gakkai Zasshi; 1994 Jul; 95(7):479. PubMed ID: 7520970
    [No Abstract]   [Full Text] [Related]  

  • 13. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Mar; 85(3):346-53. PubMed ID: 6827843
    [No Abstract]   [Full Text] [Related]  

  • 14. Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin.
    Harig F; Feyrer R; Mahmoud FO; Blum U; von der Emde J
    Thorac Cardiovasc Surg; 1999 Apr; 47(2):111-8. PubMed ID: 10363611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
    Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin-coated devices and high-dose aprotinin optimally inhibit contact system activation in an in vitro cardiopulmonary bypass model.
    Wendel HP; Heller W; Gallimore MJ
    Immunopharmacology; 1996 May; 32(1-3):128-30. PubMed ID: 8796289
    [No Abstract]   [Full Text] [Related]  

  • 17. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
    Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
    Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement.
    Wendel HP; Heller W; Gallimore MJ; Bantel H; Müller-Beissenhirtz H; Hoffmeister HE
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):41-5. PubMed ID: 7681331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of aprotinin and pentoxifylline in preventing leukocyte sequestration and lung injury caused by protamine at the end of cardiopulmonary bypass surgery.
    Ege T; Arar C; Canbaz S; Cikirikcioglu M; Sunar H; Yuksel V; Duran E
    Thorac Cardiovasc Surg; 2004 Feb; 52(1):10-5. PubMed ID: 15002070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin.
    Kipfer B; Englberger L; Gygax E; Nydegger U; Carrel T
    Transfus Apher Sci; 2003 Aug; 29(1):17-24. PubMed ID: 12877888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.